根据FDA不良事件报告系统,对1岁以下婴儿使用达普托的药监测研究
Lingling Ye1, Guimu Guo1, Hong Zhou1
1Department of Pharmacy, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China.
Scientific reports
|November 18, 2025
概括
在1岁以下的婴儿中,达普托米辛的安全性尚不确定. 这项研究使用FAERS数据确定了潜在的不良事件信号,包括肝细胞解和DRESS,突出了这一群体的风险.
科学领域:
- 药监和药物安全 药监和药物安全
- 儿科药理学 儿科药理学
- 现实世界的证据研究研究.
背景情况:
- 在1岁以下的婴儿中,达普托米辛的安全性需要进一步研究.
- 在新生儿和婴儿中关于达普托米辛不良事件 (AEs) 的现有数据有限.
- 现实世界的数据可以为特殊儿科群体的潜在安全信号提供见解.
研究的目的:
- 为了识别潜在的不良事件 (AE) 信号,与1岁以下的婴儿使用达普素相关.
- 为了利用食品和药物管理局的不良事件报告系统 (FAERS) 数据库进行药监.
- 用多个不成比例分析算法评估AE信号的强度.
主要方法:
- 从2004年第一季度到2024年第二季度利用FAERS数据库进行现实世界药监测.
- 雇员不成比例分析:报告几率比率 (ROR),比例报告比率 (PRR),MGPS和BCPNN.
- 对过去5年的数据进行了子组分析,以改进信号检测.
主要成果:
- 在1岁以下的婴儿中,在3个器官系统类别 (SOC) 中确定了8个潜在的达普托米辛AE风险信号.
- 最强的关联包括肝胆道疾病 (ROR 8.54),脏和尿道疾病 (ROR 4.55) 和感染 (ROR 3.68).
- 最重要的AE信号是肝细胞分解 (ROR 297.93) 和药物反应与乙酸性和全身症状 (DRESS) (ROR 92.54). 亚组分析证实肝细胞分解和DRESS是重要的信号.
结论:
- 在1岁以下的婴儿中发现了新的达普素AE信号,特别是肝细胞解和DRESS.
- 这些发现支持加强在这个脆弱的儿科群体中使用达普素的风险监测.
- FAERS数据库的局限性需要谨慎的解释;需要进一步的研究来确认这些安全信号.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Drug Dosing: Infants and Children
235
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
235
Pharmacokinetics in Pediatric Patients: Drug Excretion
196
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
196
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
232
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
232
Pharmacokinetics in Pediatric Patients: Drug Metabolism
179
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
179
Pharmacokinetics in Pediatric Patients: Drug Distribution
247
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
247


